

MERCK LIMITED							(Rs. in Lakhs)						
Regd. Office: Shivsagar Estate 'A', Dr. Annie Besant Road, Worli, Mumbai - 400018							STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER, 2013						
Particulars	3 months ended 30/09/2013	Preceding 3 months ended 30/06/2013	Corresponding 3 months ended 30/09/2012 in the previous year	Year to date figures for the current period ended 30/09/2013	Year to date figures for the previous period ended 30/09/2012	Previous year ended 31/12/2012	Segment Wise Revenue, Result and Capital Employed						
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Particulars	3 months ended 30/09/2013	Preceding 3 months ended 30/06/2013	Corresponding 3 months ended 30/09/2012 in the previous year	Year to date figures for the current period ended 30/09/2013	Year to date figures for the previous period ended 30/09/2012	Previous year ended 31/12/2012
								Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from operations							1. Segment Revenue						
a) Net Sales/Income from operations (Net of excise duty)	20,181.88	20,029.38	18,120.95	57,876.13	49,689.11	65,807.05	a) Pharmaceuticals	14,747.27	14,031.71	12,681.74	40,667.05	34,813.32	45,733.52
b) Other operating income	565.43	572.52	673.95	1,676.76	2,270.65	2,920.90	b) Chemicals	6,443.28	6,993.73	6,507.14	20,314.05	18,357.95	24,639.33
Total income from operations (net)	20,747.31	20,601.90	18,794.90	59,552.89	51,959.76	68,727.95	Total	21,190.55	21,025.44	19,188.88	60,981.10	53,171.27	70,372.85
2. Expenses							Less : Inter segment revenue	443.24	423.54	393.98	1,428.21	1,211.51	1,644.90
a) Cost of materials consumed	6,159.22	7,112.78	4,815.51	19,605.58	13,590.85	17,943.63	Net Sales and Other Operating Income	20,747.31	20,601.90	18,794.90	59,552.89	51,959.76	68,727.95
b) Purchases of stock-in-trade	3,941.53	4,016.97	2,933.33	10,895.04	8,539.98	11,608.69	2. Segment Results (Profit before Tax and Interest from each segment)						
c) Changes in inventories of finished goods,work-in-progress and stock in trade	(651.28)	(2,159.96)	498.13	(4,120.65)	475.89	349.14	a) Pharmaceuticals	1,734.42	1,355.80	2,523.10	4,119.96	4,968.66	6,554.67
d) Employee benefits expense	2,619.93	2,603.74	2,191.44	7,554.48	6,782.49	8,530.07	b) Chemicals	350.66	909.38	861.58	1,829.78	2,436.00	3,199.03
e) Depreciation and amortisation expense	246.72	238.37	230.22	720.89	649.35	889.77	Total	2,085.08	2,265.18	3,384.68	5,949.74	7,404.66	9,753.70
f) Other expenses	6,500.05	6,782.18	4,760.89	19,454.96	14,567.21	19,747.21	Less : Other un-allocable expenditure net off un-allocable Income	(359.55)	(285.47)	(507.86)	(1,104.42)	(1,392.20)	(1,925.30)
Total expenses	18,816.17	18,594.08	15,429.52	54,110.30	44,605.77	59,068.51	Total Profit before Tax	2,444.63	2,550.65	3,892.54	7,054.16	8,796.86	11,679.00
3. Profit from operations before other income, finance costs and exceptional items (1-2)	1,931.14	2,007.82	3,365.38	5,442.59	7,353.99	9,659.44	3. Capital Employed						
4. Other Income	513.49	542.83	527.16	1,611.57	1,442.87	2,019.56	a) Pharmaceuticals	12,904.82	12,682.71	9,132.14	12,904.82	9,132.14	7,864.43
5. Profit from ordinary activities before finance costs and exceptional items (3+4)	2,444.63	2,550.65	3,892.54	7,054.16	8,796.86	11,679.00	b) Chemicals	15,600.36	14,600.19	13,325.41	15,600.36	13,325.41	13,946.60
6. Finance Cost	-	-	-	-	-	-	c) Unallocated	24,504.38	24,149.17	24,385.61	24,504.38	24,385.61	26,555.10
7. Profit from ordinary activities before finance costs and exceptional items (5-6)	2,444.63	2,550.65	3,892.54	7,054.16	8,796.86	11,679.00	Total	53,009.56	51,432.07	46,843.16	53,009.56	46,843.16	48,366.13
8. Exceptional items	-	-	-	-	-	-							
9. Profit from ordinary activities before tax (7+8)	2,444.63	2,550.65	3,892.54	7,054.16	8,796.86	11,679.00							
10. Tax expense *	867.14	882.33	1,312.37	2,410.73	2,962.00	3,838.86							
11. Net Profit from Ordinary Activities after tax (9-10)	1,577.49	1,668.32	2,580.17	4,643.43	5,834.86	7,840.14							
12. Extraordinary items (net of tax expense)	-	-	-	-	-	-							
13. Net Profit for the period (11±12)	1,577.49	1,668.32	2,580.17	4,643.43	5,834.86	7,840.14							
14. Paid-up equity share capital (Face Value Rs 10/-)	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94	1,659.94							
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	46,706.19							
16.i Earnings per share (before extraordinary items) (of Rs 10/- each) (not annualised):													
(a) Basic	9.50	10.05	15.54	27.97	35.15	47.23							
(b) Diluted	9.50	10.05	15.54	27.97	35.15	47.23							
16.ii Earnings per share (after extraordinary items) (of Rs 10/- each) (not annualised):													
(a) Basic	9.50	10.05	15.54	27.97	35.15	47.23							
(b) Diluted	9.50	10.05	15.54	27.97	35.15	47.23							
A PARTICULARS OF SHAREHOLDING													
1 Public shareholding													
- Number of shares	80,00,158	80,00,158	80,00,158	80,00,158	80,00,158	80,00,158							
- Percentage of shareholding	48.2	48.2	48.2	48.2	48.2	48.2							
2 Promoters and Promoter Group Shareholding													
(a) Pledged/ Encumbered													
- Number of shares	-	-	-	-	-	-							
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	-	-	-	-	-	-							
- Percentage of Shares (as a % of the total share capital of the company)	-	-	-	-	-	-							
(b) Non-encumbered													
- Number of shares	85,99,224	85,99,224	85,99,224	85,99,224	85,99,224	85,99,224							
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100	100	100	100	100	100							
- Percentage of shares (as a % of the total share capital of the company)	51.8	51.8	51.8	51.8	51.8	51.8							
* Tax expense consists of:													
Current Tax	860.00	880.00	1,260.00	2,520.00	2,960.00	3,850.00							
Deferred Tax	7.14	2.33	52.37	(109.27)	2.00	(11.14)							
Particulars		3 months ended 30/09/2013											
B INVESTOR COMPLAINTS													
Pending at the beginning of the quarter		Nil											
Received during the quarter		01											
Disposed of during the quarter		01											
Remaining unresolved at the end of the quarter		Nil											
Notes :-													
1. The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 21st October, 2013. The above results were subjected to a "Limited Review" by the Statutory Auditors.													
2. Figures for the previous quarter/year have been re-grouped/re-arranged wherever necessary.													
Place : Mumbai													
Date : 21st October, 2013													
Please visit us at our website www.merck.co.in													